AIM Vaccine Statistics

Total Valuation

AIM Vaccine has a market cap or net worth of HKD 4.50 billion. The enterprise value is 6.09 billion.

Market Cap	4.50B
Enterprise Value	6.09B

Important Dates

The last earnings date was Thursday, May 29, 2025.

Earnings Date	May 29, 2025
Ex-Dividend Date	n/a

Share Statistics

AIM Vaccine has 1.23 billion shares outstanding.

Current Share Class	507.67M
Shares Outstanding	1.23B
Shares Change (YoY)	n/a
Shares Change (QoQ)	n/a
Owned by Insiders (%)	27.84%
Owned by Institutions (%)	4.85%
Float	305.24M

Valuation Ratios

PE Ratio	n/a
Forward PE	578.66
PS Ratio	3.29
PB Ratio	1.17
P/TBV Ratio	1.50
P/FCF Ratio	n/a
P/OCF Ratio	42.65
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	-20.64
EV / Sales	4.45
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-253.69

Financial Position

The company has a current ratio of 0.77, with a Debt / Equity ratio of 0.51.

Current Ratio	0.77
Quick Ratio	0.57
Debt / Equity	0.51
Debt / EBITDA	n/a
Debt / FCF	-81.63
Interest Coverage	-3.76

Financial Efficiency

Return on equity (ROE) is -7.43% and return on invested capital (ROIC) is -2.57%.

Return on Equity (ROE)	-7.43%
Return on Assets (ROA)	-1.96%
Return on Invested Capital (ROIC)	-2.57%
Return on Capital Employed (ROCE)	-5.42%
Revenue Per Employee	890,876
Profits Per Employee	-192,199
Employee Count	1,535
Asset Turnover	0.18
Inventory Turnover	0.68

Taxes

Income Tax	-13.04M
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -49.44% in the last 52 weeks. The beta is 0.15, so AIM Vaccine's price volatility has been lower than the market average.

Beta (5Y)	0.15
52-Week Price Change	-49.44%
50-Day Moving Average	3.60
200-Day Moving Average	5.39
Relative Strength Index (RSI)	43.60
Average Volume (20 Days)	1,908,251

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, AIM Vaccine had revenue of HKD 1.37 billion and -295.02 million in losses. Loss per share was -0.24.

Revenue	1.37B
Gross Profit	1.01B
Operating Income	-243.44M
Pretax Income	-309.37M
Net Income	-295.02M
EBITDA	-103.94M
EBIT	-243.44M
Loss Per Share	-0.24

Full Income Statement

Balance Sheet

The company has 633.05 million in cash and 1.96 billion in debt, giving a net cash position of -1.33 billion or -1.08 per share.

Cash & Cash Equivalents	633.05M
Total Debt	1.96B
Net Cash	-1.33B
Net Cash Per Share	-1.08
Equity (Book Value)	3.84B
Book Value Per Share	2.96
Working Capital	-747.98M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 105.56 million and capital expenditures -129.56 million, giving a free cash flow of -24.00 million.

Operating Cash Flow	105.56M
Capital Expenditures	-129.56M
Free Cash Flow	-24.00M
FCF Per Share	-0.02

Full Cash Flow Statement

Margins

Gross margin is 74.20%, with operating and profit margins of -17.80% and -21.57%.

Gross Margin	74.20%
Operating Margin	-17.80%
Pretax Margin	-22.62%
Profit Margin	-21.57%
EBITDA Margin	-7.60%
EBIT Margin	-17.80%
FCF Margin	n/a

Dividends & Yields

AIM Vaccine does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	n/a
Shareholder Yield	n/a
Earnings Yield	-6.55%
FCF Yield	-0.53%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

AIM Vaccine has an Altman Z-Score of 0.87 and a Piotroski F-Score of 5. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	0.87
Piotroski F-Score	5